These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24147083)

  • 1. Activation of the
    Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
    Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms.
    Schwartz JR; Ma J; Kamens J; Westover T; Walsh MP; Brady SW; Robert Michael J; Chen X; Montefiori L; Song G; Wu G; Wu H; Branstetter C; Hiltenbrand R; Walsh MF; Nichols KE; Maciaszek JL; Liu Y; Kumar P; Easton J; Newman S; Rubnitz JE; Mullighan CG; Pounds S; Zhang J; Gruber T; Ma X; Klco JM
    Nat Commun; 2021 Feb; 12(1):985. PubMed ID: 33579957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2.
    Bery N; Bataille CJR; Russell A; Hayes A; Raynaud F; Milhas S; Anand S; Tulmin H; Miller A; Rabbitts TH
    Sci Adv; 2021 Apr; 7(15):. PubMed ID: 33837087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.
    Mori M; Kubota Y; Durmaz A; Gurnari C; Goodings C; Adema V; Ponvilawan B; Bahaj WS; Kewan T; LaFramboise T; Meggendorfer M; Haferlach C; Barnard J; Wlodarski M; Visconte V; Haferlach T; Maciejewski JP
    Leukemia; 2023 Oct; 37(10):2082-2093. PubMed ID: 37634012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing.
    Gu M; Zwiebel M; Ong SH; Boughton N; Nomdedeu J; Basheer F; Nannya Y; Quiros PM; Ogawa S; Cazzola M; Rad R; Butler AP; Vijayabaskar MS; Vassiliou GS
    Haematologica; 2020 Jun; 105(6):e290-e293. PubMed ID: 31649132
    [No Abstract]   [Full Text] [Related]  

  • 6. Tracing the development of acute myeloid leukemia in CBL syndrome.
    Becker H; Yoshida K; Blagitko-Dorfs N; Claus R; Pantic M; Abdelkarim M; Niemöller C; Greil C; Hackanson B; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Döhner K; Schnittger S; Henneke P; Niemeyer CM; Flotho C; Pfeifer D; Ogawa S; Lübbert M
    Blood; 2014 Mar; 123(12):1883-6. PubMed ID: 24493670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of sequencing coverage bias revealed by ultra-deep sequencing of vertebrate mitochondria.
    Ekblom R; Smeds L; Ellegren H
    BMC Genomics; 2014 Jun; 15(1):467. PubMed ID: 24923674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A microglia clonal inflammatory disorder in Alzheimer's Disease.
    Vicario R; Fragkogianni S; Weber L; Lazarov T; Hu Y; Hayashi SY; Craddock BP; Socci ND; Alberdi A; Baako A; Ay O; Ogishi M; Lopez-Rodrigo E; Kappagantula R; Viale A; Iacobuzio-Donahue CA; Zhou T; Ransohoff RM; Chesworth R; ; Abdel-Wahab O; Boisson B; Elemento O; Casanova JL; Miller WT; Geissmann F
    bioRxiv; 2024 Aug; ():. PubMed ID: 38328106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
    Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
    Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
    J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In the era of next generation sequencing, is the cytogenetic analysis still important in polycythemia vera?
    Mandal PK; Kartthik S
    South Asian J Cancer; 2017; 6(2):46. PubMed ID: 28702402
    [No Abstract]   [Full Text] [Related]  

  • 13. An unusual translocation, t(1;11)(q21;q23), in a case of chronic myeloid leukemia with a cryptic Philadelphia chromosome.
    Gutiérrez LG; Noriega MF; Laudicina A; Quatrin M; Bengió RM; Larripa I
    Oncol Lett; 2017 May; 13(5):3159-3162. PubMed ID: 28521421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report.
    Hu G; Mallik DK; Yang W; Hou Y; Cheng Z; Chen P; Zhu W; Wang H; Shen L; Zhang H; Yang Z
    Breast Care (Basel); 2016 Apr; 11(2):145-7. PubMed ID: 27239178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of c-Cbl in myeloid malignancies.
    Katzav S; Schmitz ML
    Oncotarget; 2015 May; 6(13):10689-96. PubMed ID: 26028666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.
    Klampfl T; Milosevic JD; Puda A; Schönegger A; Bagienski K; Berg T; Harutyunyan AS; Gisslinger B; Rumi E; Malcovati L; Pietra D; Elena C; Della Porta MG; Pieri L; Guglielmelli P; Bock C; Doubek M; Dvorakova D; Suvajdzic N; Tomin D; Tosic N; Racil Z; Steurer M; Pavlovic S; Vannucchi AM; Cazzola M; Gisslinger H; Kralovics R
    PLoS One; 2013; 8(10):e77819. PubMed ID: 24147083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of CBL, a proto-oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia.
    Fu JF; Hsu JJ; Tang TC; Shih LY
    Genes Chromosomes Cancer; 2003 Jun; 37(2):214-9. PubMed ID: 12696071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.
    Poppe B; Vandesompele J; Schoch C; Lindvall C; Mrozek K; Bloomfield CD; Beverloo HB; Michaux L; Dastugue N; Herens C; Yigit N; De Paepe A; Hagemeijer A; Speleman F
    Blood; 2004 Jan; 103(1):229-35. PubMed ID: 12946992
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.